From the Gut to the Genome: Three Converging Breakthroughs Redefine Aging Reversal in 2026
A landmark Nature study, the first FDA-cleared epigenetic reprogramming trial, and a next-generation AI drug discovery model converged in early 2026, signaling that aging reversal science has crossed into clinical…
